NEST-1
- Generic Name
- NEST-1
A Study to Investigate the Safety and Efficacy of NST-628 Oral Tablets in Subjects With Solid Tumors
Phase 1
Recruiting
- Conditions
- MEK MutationSolid Tumor, AdultRAF Gene MutationNSCLCOncologyRas (KRAS or NRAS) Gene MutationMAPK Pathway Gene MutationMelanomaGlioma
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- Nested Therapeutics, Inc
- Target Recruit Count
- 230
- Registration Number
- NCT06326411
- Locations
- 🇺🇸
Laura & Isaac Perlmutter Cancer Center at NYU Langone Health, New York, New York, United States
🇺🇸Sarah Cannon Research Institute at Health ONE, Denver, Colorado, United States
🇺🇸UPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath